Where We Engage
Series A Readiness
Institutional investors fund companies, not just science. We help you build the story, structure, and materials that translate your program's potential into a credible, financeable investment thesis.
- Investor narrative and competitive positioning
- Development strategy aligned to value inflection
- Diligence readiness and data package review
- Deck refinement and message sharpening
Translational & Development Strategy
A scientifically strong program can still fail if the clinical and regulatory path isn't credible to investors and partners. We pressure-test your plan and help you build one that holds up.
- Preclinical-to-clinical pathway design
- IND-enabling study prioritization
- Clinical strategy and endpoint logic
- Regulatory framework and positioning
Strategic & Commercial Pressure Testing
What looks differentiated from the inside can appear commodity from the outside. We evaluate your program through the lens of investors, partners, and acquirers — before they do.
- Target product profile and market positioning
- Competitive landscape and white space assessment
- Commercial logic and peak sales framing
- Portfolio and asset prioritization
Operator experience. Investor fluency. No layers between us.
Most advisory relationships involve a senior name and a junior team. Seven Hills is different. Every engagement is led by Darren Buchwald — someone who has made the decisions your investors will scrutinize.
Built Companies, Not Just Decks
Involvement in multiple spinouts and startups results in appreciation of the hard tradeoffs founders face — operationally, scientifically, and financially.
Five Products Through FDA
Hard-won regulatory and development experience means your strategy gets tested against real-world execution, not theory.
Both Sides of the Table
Deep experience working with with investors, acquirers, and partners — and having raised capital — Seven Hills understands what actually moves decisions.
Operator Perspective
Experience leading cross functional drug development teams, portfolio committees, and investment committees in biopharma companies. Extensive commercialization and launch experience.
About the Firm
Boutique strategic counsel for biopharma companies at the inflection point.
Darren Buchwald is a biopharma builder/operator with more than three decades of experience founding, building, and scaling life science companies across the full product lifecycle. He has helped form multiple companies, contributed to five FDA-approved products, and guided more than a dozen therapeutic candidates into clinical development across oncology, autoimmunity, infectious disease, CNS disorders, and rare disease.
Darren has been a principal — not an advisor — in multiple company formations, including corporate spinouts and startups. He has done the work of translating early-stage science into development strategy, investment thesis, and executable plan. He knows what it takes to build from the inside, and what it takes to be believed from the outside.
Earlier in his career, he built and led major biopharma brands across multiple therapeutic areas — developing a hard-won discipline for taking complex science to market in a way that is both scientifically credible and commercially rigorous. That experience shapes how he thinks about development decisions, value inflection points, and competitive differentiation — not as abstractions, but as choices with consequences.
He has contributed to the FDA approval of five products and guided more than a dozen therapeutic candidates into clinical development across oncology, autoimmunity and inflammation, infectious disease, CNS disorders, and rare disease.
His executive experience spans global commercial leadership, business development, portfolio strategy, and corporate development at Forest Laboratories, Human Genome Sciences, MiddleBrook Pharmaceuticals, Emergent BioSolutions, Amyris, Tailored Therapeutics, and Baylink Biosciences. He has generated more than $2B in transactions and $1B in investments across licensing, acquisitions, venture, debt, and public offerings.
Seven Hills Advisory was founded on a straightforward premise: the quality of strategic counsel available to early-stage biopharma companies should not depend on whether they can afford a full-time C-suite or have the right connections. Darren brings that level of experience directly — to the teams, at the moment, when it matters most.
Start a Conversation
Seven Hills Advisory works with a limited number of companies and investors each year — by design. Focused engagements mean better work and better outcomes. If you are preparing for a seed or Series A, evaluating a development strategy, or seeking independent perspective before a critical decision, I'd welcome a direct conversation. The goal of an initial conversation is simply to understand your context and whether there is a meaningful way to help.Just a conversation to determine whether there's a genuine fit.
Reach Darren directly: darren@sevenhillsadvisory.net
Seven Hills Advisory LLC · Boutique strategic counsel for biopharma companies at the inflection point.